Metered dose inhalers market to reach $18.4 billion by 2034

Allied Market Research says the global metered dose inhalers market was worth $10.1 billion in 2024 and is projected to reach $18.4 billion by 2034. Growth is tied to rising asthma and COPD cases, expanding use of smart inhalers and stronger demand for portable respiratory treatment.

Why it matters: - Metered dose inhalers are a core treatment tool for asthma, COPD and other respiratory conditions. - The market outlook points to sustained demand as respiratory disease rates rise and care shifts toward portable, home-use therapies. - The forecast also signals growing interest in smarter and more compliant inhaler formats, including breath-actuated and digital devices.

What happened: - Allied Market Research published a global forecast for the metered dose inhalers market covering 2025 to 2034. - The report valued the market at $10.1 billion in 2024. - The report projects the market will reach $18.4 billion by 2034. - Allied Market Research expects the market to grow at a 6.2% compound annual growth rate from 2025 to 2034. - The report was released June 8, 2026.

The details: - The report segments the market by product type, application, distribution channel and region. - Product types include conventional MDIs and breath-actuated MDIs. - Applications include asthma, COPD and other uses. - Distribution channels include hospital pharmacies, retail pharmacies and online pharmacies. - Regions covered include North America, Europe, Asia-Pacific and LAMEA. - Conventional MDIs led the market in 2024. - Breath-actuated MDIs are expected to post the fastest growth during the forecast period. - Asthma was the largest application segment in 2024. - Hospital pharmacies generated the most revenue among distribution channels in 2024. - Online pharmacies are projected to grow the fastest among distribution channels. - North America led the market in revenue in 2024. - Asia-Pacific is projected to grow at the fastest pace through 2034. - The report links growth to rising respiratory disease prevalence, air pollution, urbanization and lifestyle changes. - The report says more than 500 million people globally are affected by asthma and COPD combined. - The report cites more than 260 million people with asthma globally, based on GINA and WHO estimates for 2024. - MDIs deliver a pre-measured dose of aerosolized medication directly to the lungs. - MDIs are used in acute care, maintenance care and home-based disease management. - The report highlights dose counters, digital inhalers and breath-actuated designs as technology trends. - Teva’s ProAir Digihaler and Propeller Health’s digital inhaler solutions are examples of connected inhaler tools cited in the report. - The report identifies misuse of inhalers as a major challenge, with nearly 70% to 80% of patients using MDIs incorrectly. - The report points to environmental pressure on traditional HFA propellants as another restraint. - The report cites low-GWP propellants such as HFO-1234ze as a possible alternative. - The report lists AstraZeneca, GlaxoSmithKline Pharmaceuticals, Chiesi Farmaceutici, Cipla, Teva Pharmaceutical Industries, Lupin, AptarGroup, Boehringer Ingelheim, Sun Pharmaceutical Industries and Zydus Lifesciences as key players. - The report includes a request sample link: Request the report sample. - The report includes a purchase inquiry link: Contact sales.

Between the lines: - The biggest growth story is not just more inhaler use. It is a shift toward devices that improve adherence, reduce user error and support remote monitoring. - Environmental regulation is becoming a market force, not just a policy issue, because propellant emissions are pushing manufacturers toward lower-carbon designs. - The fastest-growing regions and channels suggest the market is moving beyond traditional hospital care into broader consumer and digital access points.

What’s next: - Breath-actuated and smart inhalers are likely to gain more share if manufacturers can reduce misuse and improve adherence. - Generic and lower-cost inhalers may play a larger role in emerging markets where access and affordability remain barriers. - Pressure to cut emissions is expected to keep pushing product reformulation and propellant alternatives through the forecast period.

The bottom line: - Metered dose inhalers remain a large, growing respiratory care market, but future growth will depend on better usability, wider access and cleaner inhaler technology.